BioSyent Named to the TSX Venture Top 50(R) Ranking

Marketwired

MISSISSAUGA, ONTARIO--(Marketwire - Feb. 15, 2012) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX.V - News) announced today that it has been named as one of the 2012 TSX Venture Top 50 companies.

The 2012 TSX Venture 50 is an annual ranking of strong performing emerging companies listed on the TSX Venture Exchange. The TSX Venture 50 includes the top 10 companies in five major industry sectors that have been identified as leaders in Canada's public venture market. BioSyent is ranked fifth in the list of ten leading Technology and Life Sciences companies for the year. Companies are selected based on four equally weighted criteria - return on investment, trading activity, market capitalization growth, and analyst coverage. The results were obtained from data to December 31, 2011.

"With more than 2,200 companies listed on the TSX Venture Exchange, it is an honour to have BioSyent named as one of this year's TSX Venture Top 50 companies," said Rene Goehrum, President and CEO of BioSyent Inc. "Thanks to the hard work of our team and the tangible growth in both our revenue and profit, the investment community is recognizing the value in Biosyent."

More information on the TSX Venture Top 50 is available at http://www.tmxmoney.com/en/research/tsxventure50.html.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contact:
Rene C. Goehrum
BioSyent Inc.
President and CEO
www.biosyent.com

Rates

View Comments (0)